FDA grants priority review for over-the-counter naloxone nasal spray to treat opioid overdose

Contract drugmaker Emergent Biosolutions said on Tuesday its over-the-counter naloxone-based nasal spray as a treatment for suspected opioid overdose would be reviewed on a priority basis by the FDA.

Related Keywords

Maryland ,United States ,Washington ,Bhanvi Satija ,Khushi Mandowara ,Joe Biden ,Drug Administration ,Emergent Biosolutions ,Boris Peaker ,Opiant Pharmaceutical ,News ,Traffic ,Leather ,Sports ,Lassifieds ,Cars ,Jobs ,Homes ,Television ,Adio ,Salt Lake ,Utah ,Ocal ,